Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma

Perilongo, Giorgio; Maibach, Rudolf; Shafford, Elisabeth; Brugières, Laurence; Brock, Penelope; Morland, Bruce; de Camargo, Beatriz; Zsíros, József; Roebuck, Derek; Zimmermann, Arthur; C. Aronson, Daniël; Childs, Margaret; Widing, Eva; Laithier, Véronique; Plaschkes, J.; Pritchard, Jon; Scopinaro, Marcello; A. MacKinlay, Gordon; Czauderna, Piotr

doi:10.1056/nejmoa0810613

Public

Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma

Published in New England Journal of Medicine • Oct 21, 2009

Authors:

Giorgio Perilongo

Rudolf Maibach

Elisabeth Shafford

Abstract

BACKGROUND: Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level of >100 ng per milliliter). METHODS: Children with standard-risk hepato...

Subject

Medicine

Cisplatin

Hepatoblastoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!